Research programme: plasma kallikrein inhibitors - Rezolute

Drug Profile

Research programme: plasma kallikrein inhibitors - Rezolute

Alternative Names: AB 402; AB 602; ASP 400; RZ 402; RZ 602

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ActiveSite Pharmaceuticals
  • Developer ActiveSite Pharmaceuticals; Rezolute
  • Class Eye disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Diabetic retinopathy; Hereditary angioedema
  • Discontinued Stroke

Most Recent Events

  • 07 Dec 2017 XOMA and Rezolute agree to promote and develop extended release and oral plasma kallikrein inhibitors
  • 07 Dec 2017 AntriaBio is now called Rezolute
  • 17 Oct 2017 AntriaBio announces intention to submit an IND for Diabetic macular oedema in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top